Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: a randomized study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative Group

Autor: Lars Bastholt, Søren M. Bentzen, Henning T. Mouridsen, Mogens Kjaer, Ole S. Nielsen, Susanne B. Gjedde, Mads Dalmark, Erik Sandberg, Carsten Rose, Dorte Pedersen, Per Pfeiffer, Preben Jakobsen

Publikováno v: Bastholt, L, Dalmark, M, Gjedde, S B, Pfeiffer, P, Pedersen, D, Sandberg, E, Kjær, M, Mouridsen, H T, Rose, C, Nielsen, O S, Jakobsen, P & Bentzen, S M 1996, ' Dose-Response Relationship of Epirubicin in the Treatment of Postmenopausal Patients with Metastatic Breast Cancer : A Randomized Study of Epirubicin at Four Different Dose Levels Performed by the Danish Breast Cancer Cooperative Group ', Journal of Clinical Oncology, vol. 14, no. 4, pp. 1146-1155 . https://doi.org/10.1200/JCO.1996.14.4.1146

PURPOSE To test for possible correlations between dose of single-drug epirubicin and efficacy/toxicity in postmenopausal women with metastatic breast cancer. The study also included analysis of a correlation between pharmacokinetic and pharmacodynami

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d49428527f5a18d0e579725d2741ae8
https://doi.org/10.1200/jco.1996.14.4.1146

The pharmacokinetics of high-dose epirubicin and of the cardioprotector ADR-529 given together with cyclophosphamide, 5-fluorouracil, and tamoxifen in metastatic breast-cancer patients

Autor: Mansoor Raza Mirza, Preben Jakobsen, Carsten Rose, Henning T. Mouridsen, Susanne B. Gjedde, Lars Bastholt, Bente Sørensen

Publikováno v: Cancer chemotherapy and pharmacology. 35(1)

A high-pressure liquid chromatographic method for determination of the bisdioxopiperazine derivative ADR-529 (ICRF-187), a compound proven effective in protection against anthracycline-induced cardiotoxicity, has been developed. The limit of quantita

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b07bb7e6b4f630c6abb4f7047638ced
https://pubmed.ncbi.nlm.nih.gov/7987976

A randomized study of epirubicin at four different dose levels in advanced breast cancer. Feasibility of myelotoxicity prediction through single blood-sample measurement

Autor: Erik Sandberg, Dorthe Petersen, Per Pfeiffer, Preben Jakobsen, Henning T. Mouridsen, Susanne B. Gjedde, Mads Dalmark, Ole S. Nielsen, Lars Bastholt, Carsten Rose

Publikováno v: Cancer chemotherapy and pharmacology. 28(6)

Detailed pharmacokinetic analysis and subsequent evaluation of myelotoxicity were performed in 55 patients who had been randomized to 4 different doses of epirubicin (40, 60, 90 or 135 mg/m2 given i.v. every 3 weeks). A significantly positive correla

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d8412c122e797823a17d19b7277d323
https://pubmed.ncbi.nlm.nih.gov/1934250

Phase II study of tauromustine in disseminated malignant melanoma

Autor: Erik Blomquist, Jonas Bergh, Ebbe Lindegaard-Madsen, Hendrik Nolte, Henning T. Mouridsen, Susanne B. Gjedde

Publikováno v: European journal of cancerclinical oncology. 25(4)

Forty-seven patients with metastatic malignant melanoma took part in a phase II trial of tauromustine (TCNU), a new chlorethylnitrosourea based on the endogenous amino acid taurine. TCNU was given orally at a dosage of 130 mg/m2 every fifth week. No

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::10470da0f965ef6c3e06a487b0c3e127
https://pubmed.ncbi.nlm.nih.gov/2714342